RedHill Biopharma's US opaganib study for COVID-19 cleared to continue
Israeli gastrointestinal diseases specialist RedHill Biopharma (Nasdaq: RDHL) says that its US Phase II study of Yeliva (opaganib; ABC294640) in hospitalized patients with severe pneumonia linked to COVID-19, has passed its second pre-scheduled safety review by the independent Safety Oversight Committee (CSI) with a unanimous recommendation to continue the study without change.
The CSI recommendation is based on an unblinded analysis of safety data from the first 24 patients treated in the study for at least seven days. Patient recruitment for the study is 75% complete.
The US study, currently underway at eight clinical trial sites, is expected to complete recruitment this month, with data expected to follow before the end of the year. The Phase II study is not efficacy-oriented and focuses on assessing safety and identifying a signal of efficacy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze